138 results on '"Aurrekoetxea, Igor"'
Search Results
2. In Vivo Hepatic Triglyceride Secretion Rate in Antisense Oligonucleotide (ASO)-Treated Mice
3. FRI-472-YI Mitochondrial metabolism is disrupted by ciprofloxacin preventing cholangiocarcinoma cell proliferation
4. THU-210 Dysfunctional activation of the DNA damage response is associated with MASLD progression through an E2F2-dependent mechanism
5. FRI-343-YI APAP induced liver damage is prevented by activation of PPARgamma and PPAR-alpha
6. OS-101-YI Remodelling of hepatocyte cholesterol metabolism mediates colorectal liver metastasis
7. TOP-229-YI The E2F2 target glycerophosphodiester phosphodiesterase domain containing 3 is involved in MASLD progression to HCC and related dyslipidemias
8. Methionine adenosyltransferase 1a antisense oligonucleotides activate the liver-brown adipose tissue axis preventing obesity and associated hepatosteatosis
9. Role of Aramchol in steatohepatitis and fibrosis in mice.
10. Deregulated neddylation in liver fibrosis
11. The E2F2-miR34a-5p axis is involved in the biliary metabolism dysregulation in NASH
12. Targeting the E2F/MCM axis in cholangiocarcinoma halts disease progression in experimental models by rewiring lipid metabolism
13. E2F2 deficiency protects from acetaminophen-induced hepatotoxicity while E2F1 is required to prevent the devastating effects
14. E2F2-promoted DNA damage in NASH worsens the metabolic scenario
15. Hypothalamic AMPK-ER Stress-JNK1 Axis Mediates the Central Actions of Thyroid Hormones on Energy Balance
16. Data from E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment
17. Supplementary Information from E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment
18. Supplementary Table 1 from E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment
19. Supplementary Data from E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment
20. Supplementary Table 2 from E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment
21. Supplementary Figures from E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment
22. Supplementary Table 3 from E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment
23. S-Adenosylmethionine increases circulating very-low density lipoprotein clearance in non-alcoholic fatty liver disease
24. Targeting E2F Sensitizes Prostate Cancer Cells to Drug-Induced Replication Stress by Promoting Unscheduled CDK1 Activity
25. The uptake of extracellular lipids promotes cholangiocarcinoma progression
26. miR34a-5p is a target of E2F2 transcription factor in MAFLD-related HCC
27. Methionine adenosyltransferase 1a antisense oligonucleotides induce the fibroblast growth factor 21-driven recovery from obesity and associated hepatoesteatosis
28. The DNA damage response is involved in the metabolic dysregulation of MAFLD patients via inefficient fatty acid oxidation
29. Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids
30. Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids
31. Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids
32. Serum oxidizability and antioxidant status in patients undergoing in vitro fertilization
33. E2F1 and E2F2-mediated repression of CPT2 establishes a lipid-rich tumor-promoting environment
34. E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment
35. WED-408 - E2F2-promoted DNA damage in NASH worsens the metabolic scenario
36. WED-404 - The E2F2-miR34a-5p axis is involved in the biliary metabolism dysregulation in NASH
37. SAT-215 - Targeting the E2F/MCM axis in cholangiocarcinoma halts disease progression in experimental models by rewiring lipid metabolism
38. FRI-395 - E2F2 deficiency protects from acetaminophen-induced hepatotoxicity while E2F1 is required to prevent the devastating effects
39. Liver osteopontin is required to prevent the progression of age-related nonalcoholic fatty liver disease
40. Detection of catechol-O-methyltransferase Val158Met polymorphism by a simple one-step tetra-primer amplification refractory mutation system-PCR
41. Excess S-adenosylmethionine reroutes phosphatidylethanolamine towards phosphatidylcholine and triglyceride synthesis
42. Methionine adenosyltransferase 1A gene deletion disrupts hepatic very low-density lipoprotein assembly in mice
43. Liver osteopontin is required to prevent the progression of age‐related nonalcoholic fatty liver disease
44. Methionine adenosyltransferase 1A gene deletion disrupts hepatic very low-density lipoprotein assembly in mice
45. Neddylation inhibition prevents acetaminophen-induced liver damage by enhancing the anabolic cardiolipin pathway
46. Doxorubicin Increases Intracellular Diacylglycerol by the Mobilization of Choline-Enriched Phospholipids in Rat Hepatocytes
47. Intracellular Diacylglycerol Accumulation Induced by Doxorubicin in Rat Hepatocytes: Potential Involvement of Phospholipases C and D
48. PS-008-E2F2 mediated repression of fatty acid B-oxidation is mitigated through CREB1 in progressive non-alcoholic fatty liver disease
49. An imbalance in progenitor cell populations reflects tumour progression in breast cancer primary culture models
50. Hypothalamic AMPK-ER Stress-JNK1 Axis Mediates the Central Actions of Thyroid Hormones on Energy Balance
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.